Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

NASDAQ:BPMC

Overview | Financials
Company Name Blueprint Medicines Corporation
Symbol BPMC
Currency USD
Price 89.58
Market Cap 5,724,699,480
Dividend Yield 0%
52-week-range 80.675 - 121.9
Industry Biotechnology
Sector Healthcare
CEO Ms. Kathryn Haviland
Website https://www.blueprintmedicines.com

An error occurred while fetching data.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of

Related Stocks

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

44.36 USD

CureVac N.V. logo

CureVac N.V.

CVAC

3.01 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

79.97 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

39.34 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

9.14 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

98.94 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Natera, Inc. logo

Natera, Inc.

NTRA

148.22 USD

Financials

Numbers are in millions USD

Numbers are in millions USD